Release – Lifeist Wellness to Release Fourth Quarter and Full Year 2021 Results on March 25 2022

 



Lifeist Wellness to Release Fourth Quarter and Full Year 2021 Results on March 25, 2022

Research, News, and Market Data on Lifeist Wellness

 

TORONTO, March 03, 2022 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced that it intends to release its financial results for the fiscal fourth quarter and full year ended November 30, 2021, on Friday, March 25, 2022, before the market open.

In addition, the Company provided the following corporate updates:

Share Issuance Related to CannMart Labs Inc.

Lifeist intends to issue an aggregate of 3,481,912 common shares (issued at a deemed price of $0.0774, which is equal to the seven-day volume weighted average per common share for the trading period up to and including March 3, 2022), without a hold period, as payment of the fifth tranche of the remaining base purchase price to the vendors under the share purchase agreement for the acquisition of CannMart Labs Inc. The issuance is considered to be a shares-for-debt transaction under the policies of the TSX-V and remains subject to TSX-V approval.

Australia Flooding

A major flooding event has occurred in Queensland and New South Wales, Australia, resulting in property damage and loss of life throughout the region and including in Brisbane where the Company’s wholly owned subsidiary Australian Vaporizers Pty Limited (“AV”) leases a warehouse facility. Thankfully, the Company can report that all members of the AV team are safe and accounted for, though the business did suffer partial loss of inventory and is experiencing business interruption. Whilst any disruption to any business is not welcome, the AV team is working diligently to resume standard operations as soon as possible and while the near-term impact is still being fully quantified, the Company is confident in AV’s ability for a quick and full recovery due to its superior customer service, high repeat customer rate, and the measures already put into place to maintain customer loyalty. Furthermore, AV will take this opportunity to instigate initiatives to optimize operations and set future foundations for continued growth by investigating expansion into new premises.

“First and foremost, my heart goes out to all those affected by the flooding,” said Meni Morim, CEO of Lifeist. “Unfortunate as it is, thanks to our amazing can-do team at AV, this challenge also presents an opportunity to accelerate improvement and growth. The AV team’s ‘build back better’ initiative will see the operation emerge better and stronger and consolidate its position as one of Australia’s pre-eminent sellers of vaporizers and smoking accessories.”

About Lifeist Wellness Inc.

Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards; CannMart Labs, a BHO extraction facility for the production of high margin cannabis 2.0 products; the CannMart.com marketplace, which provides U.S. customers with access to hemp-derived CBD and smoking accessories; Australian Vapes, Australia’s largest online retailer of vaporizers and accessories; Findify, a leading AI-powered search and discovery platform; and Mikra, a biosciences and consumer wellness company seeking to develop innovative therapies for cellular health.

Information on Lifeist and its businesses can be accessed through the links below:

www.lifeist.com
www.cannmart.com
www.australianvaporizers.com.au
www.wearemikra.com

Contacts

Lifeist Wellness Inc.
Meni Morim, CEO
Matt Chesler, CFA, Investor Relations
Ph: 647-362-0390
Email: ir@lifeist.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Forward Looking Information

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, including, without limitation, statements related to the issuance of shares as payment for the fifth tranche of the remaining base purchase price to the vendors under the share purchase agreement for the acquisition of CannMart Labs Inc. and the anticipated growth and improvement prospects of AV including the potential expansion into new premises as a result of the flooding, are made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, its ability to obtain TSX-V approval for the shares for debt transaction and AV’s ability to quickly resume business activities, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: the failure to obtain the requisite approval of the TSX-V for the shares-for-debt issuance, and the inability of AV to resume standard operations as soon as possible or as anticipated, and AV’s inability to find new adequate premises on economic terms, if at all. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Source: Lifeist Wellness Inc.

Release – Ocugen Provides an Update on its COVAXIN Pediatric 2-18 Emergency Use Authorization EUA Request



Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request

Research, News, and Market Data on Ocugen

 

MALVERN, Pa., March 04, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that the U.S. Food and Drug Administration (FDA), at this time, has declined to issue an EUA for COVAXIN™ for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age. Ocugen intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN™.

About Ocugen, Inc.
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, our intent to work with the FDA with respect to the regulatory pathway for COVAXIN. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
IR@Ocugen.com

Please submit investor-related inquiries to: IR@ocugen.com

Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request



Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request

Research, News, and Market Data on Ocugen

 

MALVERN, Pa., March 04, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that the U.S. Food and Drug Administration (FDA), at this time, has declined to issue an EUA for COVAXIN™ for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age. Ocugen intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN™.

About Ocugen, Inc.
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, our intent to work with the FDA with respect to the regulatory pathway for COVAXIN. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
IR@Ocugen.com

Please submit investor-related inquiries to: IR@ocugen.com

Lifeist Wellness to Release Fourth Quarter and Full Year 2021 Results on March 25, 2022

 



Lifeist Wellness to Release Fourth Quarter and Full Year 2021 Results on March 25, 2022

Research, News, and Market Data on Lifeist Wellness

 

TORONTO, March 03, 2022 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced that it intends to release its financial results for the fiscal fourth quarter and full year ended November 30, 2021, on Friday, March 25, 2022, before the market open.

In addition, the Company provided the following corporate updates:

Share Issuance Related to CannMart Labs Inc.

Lifeist intends to issue an aggregate of 3,481,912 common shares (issued at a deemed price of $0.0774, which is equal to the seven-day volume weighted average per common share for the trading period up to and including March 3, 2022), without a hold period, as payment of the fifth tranche of the remaining base purchase price to the vendors under the share purchase agreement for the acquisition of CannMart Labs Inc. The issuance is considered to be a shares-for-debt transaction under the policies of the TSX-V and remains subject to TSX-V approval.

Australia Flooding

A major flooding event has occurred in Queensland and New South Wales, Australia, resulting in property damage and loss of life throughout the region and including in Brisbane where the Company’s wholly owned subsidiary Australian Vaporizers Pty Limited (“AV”) leases a warehouse facility. Thankfully, the Company can report that all members of the AV team are safe and accounted for, though the business did suffer partial loss of inventory and is experiencing business interruption. Whilst any disruption to any business is not welcome, the AV team is working diligently to resume standard operations as soon as possible and while the near-term impact is still being fully quantified, the Company is confident in AV’s ability for a quick and full recovery due to its superior customer service, high repeat customer rate, and the measures already put into place to maintain customer loyalty. Furthermore, AV will take this opportunity to instigate initiatives to optimize operations and set future foundations for continued growth by investigating expansion into new premises.

“First and foremost, my heart goes out to all those affected by the flooding,” said Meni Morim, CEO of Lifeist. “Unfortunate as it is, thanks to our amazing can-do team at AV, this challenge also presents an opportunity to accelerate improvement and growth. The AV team’s ‘build back better’ initiative will see the operation emerge better and stronger and consolidate its position as one of Australia’s pre-eminent sellers of vaporizers and smoking accessories.”

About Lifeist Wellness Inc.

Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards; CannMart Labs, a BHO extraction facility for the production of high margin cannabis 2.0 products; the CannMart.com marketplace, which provides U.S. customers with access to hemp-derived CBD and smoking accessories; Australian Vapes, Australia’s largest online retailer of vaporizers and accessories; Findify, a leading AI-powered search and discovery platform; and Mikra, a biosciences and consumer wellness company seeking to develop innovative therapies for cellular health.

Information on Lifeist and its businesses can be accessed through the links below:

www.lifeist.com
www.cannmart.com
www.australianvaporizers.com.au
www.wearemikra.com

Contacts

Lifeist Wellness Inc.
Meni Morim, CEO
Matt Chesler, CFA, Investor Relations
Ph: 647-362-0390
Email: ir@lifeist.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Forward Looking Information

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, including, without limitation, statements related to the issuance of shares as payment for the fifth tranche of the remaining base purchase price to the vendors under the share purchase agreement for the acquisition of CannMart Labs Inc. and the anticipated growth and improvement prospects of AV including the potential expansion into new premises as a result of the flooding, are made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, its ability to obtain TSX-V approval for the shares for debt transaction and AV’s ability to quickly resume business activities, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: the failure to obtain the requisite approval of the TSX-V for the shares-for-debt issuance, and the inability of AV to resume standard operations as soon as possible or as anticipated, and AV’s inability to find new adequate premises on economic terms, if at all. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Source: Lifeist Wellness Inc.

Release – Cocrystal Pharma to Participate in Upcoming Investment Conferences



Cocrystal Pharma to Participate in Upcoming Investment Conferences

Research, News, and Market Data on Cocrystal Pharma

 

BOTHELL, Wash., March 03, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investment conferences as follows:

  • Q1 Investor Summit Virtual Small & Micro Cap Conference being held March 8-9. Cocrystal senior management will present a company overview on March 9 at 11:45 a.m. Eastern time (8:45 a.m. Pacific time). A webcast of the presentation will be available live and archived here.

  • 34th Annual Roth Conference being held March 13-15 at the Ritz-Carlton, Laguna Niguel in Dana Point, Calif.

“This is an exciting time at Cocrystal as we expect enrollment to begin shortly in our influenza A Phase 1 trial. We also plan to initiate first-in-human studies later this year with two different SARS-CoV-2 antivirals as potential oral and inhalation COVID-19 treatments,” said Sam Lee, Ph.D., Cocrystal’s President and interim co-CEO. “We are pleased to share our exciting plans with investors at these two conferences.”

“Given the growing global need for effective, safe antiviral treatments, we are rapidly advancing the development of compounds for multiple high-value indications,” said James Martin, CFO and interim co-CEO. “Our strong cash position and debt-free balance sheet position us to execute on our active clinical plans.”

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our expected enrollments to begin shortly in our influenza A Phase 1 trial, plans to initiate first-in-human studies later this year with two different SARS-CoV-2 antivirals as potential oral and inhalation COVID-19 treatments and the rapid advancement of the development of compounds for multiple high value indications. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from supply chain disruptions on our ability to obtain products including raw materials and test animals as well as similar problems with our vendors and our current CRO and future CROs and CMOs, the impact of the COVID-19 pandemic including new variants on the national and global economy, the cooperation of the FDA in accelerating development in our COVID-19 program, our collaboration partners’ technology and software performing as expected, the results of future preclinical and clinical trials, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

Source: Cocrystal Pharma, Inc.

Release – electroCore to Announce Fourth Quarter and Year Ended December 31, 2021 Financial Results



electroCore to Announce Fourth Quarter and Year Ended December 31, 2021 Financial Results on Thursday, March 10

News and Market Data on electroCore

 

Conference Call to be Held at 4:30 PM Eastern Standard Time

ROCKAWAY, N.J.
March 03, 2022 (GLOBE NEWSWIRE) — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the fourth quarter and year ended 
December 31, 2021, after the close of the market on 
Thursday, March 10, 2022. Management will host a conference call and webcast at 
4:30 PM Eastern Standard Time to discuss the financial results and answer questions.

Thursday, March 10, 20224:30 PM Eastern Standard Time
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13726544
Webcast: electroCore Earnings Webcast

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com

Investors:
Rich Cockrell

CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
jackie.dorsky@electrocore.com

electroCore to Announce Fourth Quarter and Year Ended December 31, 2021 Financial Results on Thursday, March 10



electroCore to Announce Fourth Quarter and Year Ended December 31, 2021 Financial Results on Thursday, March 10

News and Market Data on electroCore

 

Conference Call to be Held at 4:30 PM Eastern Standard Time

ROCKAWAY, N.J.
March 03, 2022 (GLOBE NEWSWIRE) — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the fourth quarter and year ended 
December 31, 2021, after the close of the market on 
Thursday, March 10, 2022. Management will host a conference call and webcast at 
4:30 PM Eastern Standard Time to discuss the financial results and answer questions.

Thursday, March 10, 20224:30 PM Eastern Standard Time
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13726544
Webcast: electroCore Earnings Webcast

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com

Investors:
Rich Cockrell

CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
jackie.dorsky@electrocore.com

Cocrystal Pharma to Participate in Upcoming Investment Conferences



Cocrystal Pharma to Participate in Upcoming Investment Conferences

Research, News, and Market Data on Cocrystal Pharma

 

BOTHELL, Wash., March 03, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investment conferences as follows:

  • Q1 Investor Summit Virtual Small & Micro Cap Conference being held March 8-9. Cocrystal senior management will present a company overview on March 9 at 11:45 a.m. Eastern time (8:45 a.m. Pacific time). A webcast of the presentation will be available live and archived here.

  • 34th Annual Roth Conference being held March 13-15 at the Ritz-Carlton, Laguna Niguel in Dana Point, Calif.

“This is an exciting time at Cocrystal as we expect enrollment to begin shortly in our influenza A Phase 1 trial. We also plan to initiate first-in-human studies later this year with two different SARS-CoV-2 antivirals as potential oral and inhalation COVID-19 treatments,” said Sam Lee, Ph.D., Cocrystal’s President and interim co-CEO. “We are pleased to share our exciting plans with investors at these two conferences.”

“Given the growing global need for effective, safe antiviral treatments, we are rapidly advancing the development of compounds for multiple high-value indications,” said James Martin, CFO and interim co-CEO. “Our strong cash position and debt-free balance sheet position us to execute on our active clinical plans.”

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our expected enrollments to begin shortly in our influenza A Phase 1 trial, plans to initiate first-in-human studies later this year with two different SARS-CoV-2 antivirals as potential oral and inhalation COVID-19 treatments and the rapid advancement of the development of compounds for multiple high value indications. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from supply chain disruptions on our ability to obtain products including raw materials and test animals as well as similar problems with our vendors and our current CRO and future CROs and CMOs, the impact of the COVID-19 pandemic including new variants on the national and global economy, the cooperation of the FDA in accelerating development in our COVID-19 program, our collaboration partners’ technology and software performing as expected, the results of future preclinical and clinical trials, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

Source: Cocrystal Pharma, Inc.

Release – Ceapro Bolsters Board of Directors with Appointment of Top Executive from Global Pharmaceutical Industry



Ceapro Bolsters Board of Directors with Appointment of Top Executive from Global Pharmaceutical Industry

Research, News, and Market Data on Ceapro

 

RONNIE MILLER, PRESIDENT AND CEO OF ROCHE CANADA FROM 2000-2022 RETIRING AFTER 43 YEARS OF LEADERSHIP SERVICE IN THE PHARMACEUTICAL INDUSTRY JOINS THE COMPANY’S BOARD OF DIRECTORS

EDMONTON, Alberta, March 02, 2022 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment of leading international pharmaceutical industry executive, Ronnie Miller, to its Board of Directors.

Glenn Rourke, MBA, Chairman of the Board, stated, “We are delighted and honored to welcome Mr. Miller to our Board of Directors. He is an accomplished global executive with exceptional leadership skills and recognized achievements at all levels in the healthcare industry. With his vast expertise and successful track record, we believe Mr. Miller is the ideal candidate to provide guidance to Ceapro’s leadership team to successfully bring it to the next level as a life sciences company.”

Mr. Miller brings more than 43 years of extensive and broad leadership experience in the pharmaceutical industry. Until March 2022, he served as President and CEO of Hoffmann-La Roche Limited (Roche Canada). In his 22-year tenure in this role, he was responsible for the growth and success of the Canadian Pharmaceuticals Division, particularly as it relates to Roche’s mandate of developing and delivering innovative healthcare solutions for Canadians. Prior to his appointment as President and CEO, Mr. Miller advanced through a series of successive sales and management positions across the industry to become the National Sales Manager for Roche in the United Kingdom in 1988 and continued to move globally as a Product Manager in Switzerland and Deputy Divisional Director of the Pharmaceutical Division in Japan. He moved back to Switzerland to head up a global product launch before returning to the UK as Pharmaceuticals Director.

In addition to managing Roche Canada where he pioneered global operating models, Mr. Miller was heavily involved in the Canadian Healthcare Ecosystem. He was re-elected as Chairman of the Board of Directors of Innovative Medicines Canada (IMC), the national association representing Canada’s research-based pharmaceutical companies, from 2019 to 2022. Additionally, he served as Chairman of the IMC Board in 2007 and has since fulfilled two subsequent terms as Past Chair. Prior to this, Mr. Miller was the Chair of the IMC Prairies Core Team and sat as Co-Chair of the Health Research Foundation. He also served on several committees including the IMC Public Affairs, Stakeholder Relations, the British Columbia Sub-Committee, and was Chair of the Federal Affairs/FPT Relations Standing Committee.

Over the course of his career some of his major accomplishments include, managing to get the Montreal Heart Institute designated as the hub for translational medicine studying cardiometabolic disease in the global network of Roche International; launching the National Artificial Intelligence Centre of Excellence to drive digital intelligence in Health in 2020; and convincing Swiss Parent Company Hoffmann-La Roche to locate its Global Pharma Technical Operations in Mississauga, Ontario; a $500 million investment.

Mr. Miller commented, “It is my great pleasure to join the Ceapro Board of Directors at this important time as the Company expands its natural ingredient product expertise into additional potential therapeutic indications. To-date the board and management team have built a solid foundation by putting all the pieces in place for long-term growth. As the Company continues to progress, I look forward to actively working alongside the team to maximize the potential and value of Ceapro.”

Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, added, “Mr. Miller brings invaluable experience in managing and building international pharmaceutical companies and especially in developing and mentoring top talented people who fosters innovation for the benefit of patients. We firmly believe that his business acumen combined with his successful business development track record and vast industry network will prove to be invaluable as we expand our business model though the development of natural products and technology platforms into the expansive nutraceutical and pharmaceutical markets.”

With his Board appointment, Mr. Miller was granted options to get 150,000 common shares of Ceapro, each with an exercise price according to TSX-V regulations. Each grant vests in three equal installments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of five years from the date of grant.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Source: Ceapro Inc.

Release – ProMIS Neurosciences PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimers disease



ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease

News and Market Data on ProMIS Neurosciences

 

Transgenic mouse model reflects latest scientific understanding of disease – toxic oligomers of amyloid create cognitive deficit

TORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, announced today that PMN310, its lead antibody therapeutic candidate for Alzheimer’s disease (AD), showed a significant cognitive benefit in a widely recognized animal model of AD.

The APP/L mouse is a “transgenic” model of AD in which human amyloid-beta oligomers lead to cognitive deficits. In this model, treatment with PMN310 which selectively targets toxic oligomers of amyloid-beta preserved memory using the water maze readout, to the extent that the PMN310 treated mice were indistinguishable from “non-transgenic” control mice.     

“This model closely aligns with the most current understanding of the biology of Alzheimer’s disease, that small clumps of misfolded amyloid-beta (toxic oligomers) are the most pathogenic species1”, stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. “In our opinion, studies in transgenic mouse models that focus on plaque removal or monomer depletion are not representative of human disease. Indeed, drug candidates that showed plaque reduction in animal models were disappointing in the clinic, and targeting amyloid monomers which worked in these models, universally failed in clinical trials.”

This positive result builds on earlier in vivo data for PMN310. We have previously published2 on the protective activity of PMN310 in a novel object recognition model where toxic oligomers of amyloid-beta are injected in the brain of mice to create a memory deficit. In this model, co-injection of PMN310 prevented the loss of memory caused by toxic oligomers.

Commenting on today’s announcement, ProMIS Chairman and CEO, Eugene Williams stated: “The observed positive outcome with systemic administration of PMN310 is very encouraging, as PMN310 is on track for an IND filing by year end in its initial formulation for intravenous/infusion delivery. In parallel, we are also progressing a potential subcutaneous injection form of PMN310.”   

1Cline E et al. 2018. The amyloid- oligomer hypothesis: beginning of the third decade. Journal of Alzheimer’s disease, 64, S567-S610.
2Gibbs E et al. 2019.  A rationally designed humanized antibody selective for amyloid beta oligomers in Alzheimer’s disease.  Scientific Reports 9: 9870.   https://doi.org/10.1038/s41598-019-46306-5

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF
Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease



ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease

News and Market Data on ProMIS Neurosciences

 

Transgenic mouse model reflects latest scientific understanding of disease – toxic oligomers of amyloid create cognitive deficit

TORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, announced today that PMN310, its lead antibody therapeutic candidate for Alzheimer’s disease (AD), showed a significant cognitive benefit in a widely recognized animal model of AD.

The APP/L mouse is a “transgenic” model of AD in which human amyloid-beta oligomers lead to cognitive deficits. In this model, treatment with PMN310 which selectively targets toxic oligomers of amyloid-beta preserved memory using the water maze readout, to the extent that the PMN310 treated mice were indistinguishable from “non-transgenic” control mice.     

“This model closely aligns with the most current understanding of the biology of Alzheimer’s disease, that small clumps of misfolded amyloid-beta (toxic oligomers) are the most pathogenic species1”, stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. “In our opinion, studies in transgenic mouse models that focus on plaque removal or monomer depletion are not representative of human disease. Indeed, drug candidates that showed plaque reduction in animal models were disappointing in the clinic, and targeting amyloid monomers which worked in these models, universally failed in clinical trials.”

This positive result builds on earlier in vivo data for PMN310. We have previously published2 on the protective activity of PMN310 in a novel object recognition model where toxic oligomers of amyloid-beta are injected in the brain of mice to create a memory deficit. In this model, co-injection of PMN310 prevented the loss of memory caused by toxic oligomers.

Commenting on today’s announcement, ProMIS Chairman and CEO, Eugene Williams stated: “The observed positive outcome with systemic administration of PMN310 is very encouraging, as PMN310 is on track for an IND filing by year end in its initial formulation for intravenous/infusion delivery. In parallel, we are also progressing a potential subcutaneous injection form of PMN310.”   

1Cline E et al. 2018. The amyloid- oligomer hypothesis: beginning of the third decade. Journal of Alzheimer’s disease, 64, S567-S610.
2Gibbs E et al. 2019.  A rationally designed humanized antibody selective for amyloid beta oligomers in Alzheimer’s disease.  Scientific Reports 9: 9870.   https://doi.org/10.1038/s41598-019-46306-5

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF
Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: ProMIS Neurosciences Inc.

Ceapro Bolsters Board of Directors with Appointment of Top Executive from Global Pharmaceutical Industry



Ceapro Bolsters Board of Directors with Appointment of Top Executive from Global Pharmaceutical Industry

Research, News, and Market Data on Ceapro

 

RONNIE MILLER, PRESIDENT AND CEO OF ROCHE CANADA FROM 2000-2022 RETIRING AFTER 43 YEARS OF LEADERSHIP SERVICE IN THE PHARMACEUTICAL INDUSTRY JOINS THE COMPANY’S BOARD OF DIRECTORS

EDMONTON, Alberta, March 02, 2022 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment of leading international pharmaceutical industry executive, Ronnie Miller, to its Board of Directors.

Glenn Rourke, MBA, Chairman of the Board, stated, “We are delighted and honored to welcome Mr. Miller to our Board of Directors. He is an accomplished global executive with exceptional leadership skills and recognized achievements at all levels in the healthcare industry. With his vast expertise and successful track record, we believe Mr. Miller is the ideal candidate to provide guidance to Ceapro’s leadership team to successfully bring it to the next level as a life sciences company.”

Mr. Miller brings more than 43 years of extensive and broad leadership experience in the pharmaceutical industry. Until March 2022, he served as President and CEO of Hoffmann-La Roche Limited (Roche Canada). In his 22-year tenure in this role, he was responsible for the growth and success of the Canadian Pharmaceuticals Division, particularly as it relates to Roche’s mandate of developing and delivering innovative healthcare solutions for Canadians. Prior to his appointment as President and CEO, Mr. Miller advanced through a series of successive sales and management positions across the industry to become the National Sales Manager for Roche in the United Kingdom in 1988 and continued to move globally as a Product Manager in Switzerland and Deputy Divisional Director of the Pharmaceutical Division in Japan. He moved back to Switzerland to head up a global product launch before returning to the UK as Pharmaceuticals Director.

In addition to managing Roche Canada where he pioneered global operating models, Mr. Miller was heavily involved in the Canadian Healthcare Ecosystem. He was re-elected as Chairman of the Board of Directors of Innovative Medicines Canada (IMC), the national association representing Canada’s research-based pharmaceutical companies, from 2019 to 2022. Additionally, he served as Chairman of the IMC Board in 2007 and has since fulfilled two subsequent terms as Past Chair. Prior to this, Mr. Miller was the Chair of the IMC Prairies Core Team and sat as Co-Chair of the Health Research Foundation. He also served on several committees including the IMC Public Affairs, Stakeholder Relations, the British Columbia Sub-Committee, and was Chair of the Federal Affairs/FPT Relations Standing Committee.

Over the course of his career some of his major accomplishments include, managing to get the Montreal Heart Institute designated as the hub for translational medicine studying cardiometabolic disease in the global network of Roche International; launching the National Artificial Intelligence Centre of Excellence to drive digital intelligence in Health in 2020; and convincing Swiss Parent Company Hoffmann-La Roche to locate its Global Pharma Technical Operations in Mississauga, Ontario; a $500 million investment.

Mr. Miller commented, “It is my great pleasure to join the Ceapro Board of Directors at this important time as the Company expands its natural ingredient product expertise into additional potential therapeutic indications. To-date the board and management team have built a solid foundation by putting all the pieces in place for long-term growth. As the Company continues to progress, I look forward to actively working alongside the team to maximize the potential and value of Ceapro.”

Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, added, “Mr. Miller brings invaluable experience in managing and building international pharmaceutical companies and especially in developing and mentoring top talented people who fosters innovation for the benefit of patients. We firmly believe that his business acumen combined with his successful business development track record and vast industry network will prove to be invaluable as we expand our business model though the development of natural products and technology platforms into the expansive nutraceutical and pharmaceutical markets.”

With his Board appointment, Mr. Miller was granted options to get 150,000 common shares of Ceapro, each with an exercise price according to TSX-V regulations. Each grant vests in three equal installments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of five years from the date of grant.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Source: Ceapro Inc.

Release – Lineage Cell Therapeutics To Report Fourth Quarter And Full Year 2021 Financial Results



Lineage Cell Therapeutics To Report Fourth Quarter And Full Year 2021 Financial Results And Provide Business Update On March 10, 2022

Research, News, and Market Data on Lineage Cell Therapeutics

 

CARLSBAD, Calif.–(BUSINESS WIRE)–Mar. 1, 2022– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2021 financial and operating results on 
Thursday, March 10, 2022, following the close of the 
U.S. financial markets. Lineage management will also host a conference call and webcast on 
Thursday, March 10, 2022, at 
4:30 p.m. Eastern Time/
1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2021 financial and operating results and to provide a business update.

Interested parties may access the conference call by dialing (866) 888-8633 from the 
U.S. and 
Canada and (636) 812-6629 from elsewhere outside the 
U.S. and 
Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through 
March 18, 2022, by dialing (855) 859-2056 from the 
U.S. and 
Canada and (404) 537-3406 from elsewhere outside the 
U.S. and 
Canada and entering conference ID number 7718167.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and 
Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Mike Biega
(Mbiega@soleburytrout.com)
(617) 221-9660

Russo Partners – Media Relations
Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.